LEADER 01408nas  2200469-  450 
001 996321302203316
005 20230522213016.0
011   $a2574-173X
035   $a(DE-599)ZDB2942336-3
035   $a(OCoLC)1000299901
035   $a(CKB)4100000001115627
035   $a(CONSER)--2017202904
035   $a(EXLCZ)994100000001115627
100   $a20170810a20189999  ---         a
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aNeuropsychopharmacology reports
210  1$a[Hoboken, NJ] :$cJohn Wiley & Sons, Inc.,$d[2018]-
215   $a1 online resource
300   $aRefereed/Peer-reviewed
531 0 $aNeuropsychopharmacol. rep.
531 10$aNeuropsychopharmacol Rep
606   $aNeuropsychopharmacology$vPeriodicals
606   $aNeuropharmacology
606   $aPsychopharmacology
606   $aNeuropsychopharmacology$2fast$3(OCoLC)fst01036504
608   $aPeriodical.
608   $aPeriodicals.$2fast
615  0$aNeuropsychopharmacology
615 12$aNeuropharmacology.
615 22$aPsychopharmacology.
615  7$aNeuropsychopharmacology.
676   $a615.78
712 02$aJohn Wiley & Sons.
712 02$aNihon Shinkei Seishin Yakuri Gakkai,
906   $aJOURNAL
912   $a996321302203316
996   $aNeuropsychopharmacology reports$92276212
997   $aUNISA